← Research & Industry News
External source
Moderna mRNA vaccine almost halves the risk of skin cancer returning
Long-awaited results from phase III trial show huge benefits for treatment-resistant melanoma.
- Published by
- Nature
- Evidence type
- Clinical
Long-awaited results from phase III trial show huge benefits for treatment-resistant melanoma.
This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at Nature.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.